JASPER THERAPEUTICS INC (JSPR) Stock Price, Forecast & Analysis
USA - NASDAQ:JSPR - US4718712023 - Common Stock
JSPR Key Statistics, Chart & Performance
The current stock price of JSPR is 1.78 USD. In the past month the price decreased by -25.83%. In the past year, price decreased by -92.74%.
JSPR Latest News, Press Relases and Analysis
JSPR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About JSPR
Company Profile
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 64 full-time employees. The company went IPO on 2019-11-20. The firm is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The firm's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. The company is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
Company Info
JASPER THERAPEUTICS INC
2200 Bridge Pkwy Suite #102
Redwood City CALIFORNIA US
CEO: Bala Venkataraman
Employees: 64
Phone: 16505491400
JASPER THERAPEUTICS INC / JSPR FAQ
What does JASPER THERAPEUTICS INC do?
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 64 full-time employees. The company went IPO on 2019-11-20. The firm is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The firm's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. The company is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
What is the current price of JSPR stock?
The current stock price of JSPR is 1.78 USD. The price decreased by -2.73% in the last trading session.
Does JSPR stock pay dividends?
JSPR does not pay a dividend.
What is the ChartMill rating of JASPER THERAPEUTICS INC stock?
JSPR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of JSPR stock?
JASPER THERAPEUTICS INC (JSPR) has a market capitalization of 49.64M USD. This makes JSPR a Nano Cap stock.
JSPR Technical Analysis
JSPR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to JSPR. While JSPR seems to be doing ok healthwise, there are quite some concerns on its profitability.
JSPR Financial Highlights
Over the last trailing twelve months JSPR reported a non-GAAP Earnings per Share(EPS) of -6.01. The EPS decreased by -17.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -195.67% | ||
| ROE | -386.89% | ||
| Debt/Equity | 0 |
JSPR Forecast & Estimates
15 analysts have analysed JSPR and the average price target is 13.09 USD. This implies a price increase of 635.39% is expected in the next year compared to the current price of 1.78.